Belimumab denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for belimumab are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Imposes Quantity Limits on Belimumab

Belimumab (Benlysta) is administered on a defined dosing schedule described in the FDA-approved prescribing information. UnitedHealthcare's quantity-limit policies are designed to align reimbursement with that labeled schedule. A quantity-limit denial typically occurs when the dispensed or billed quantity exceeds what the plan's policy authorizes per dispensing period — this can happen because of differences in vial sizes, rounding conventions, body-weight-based dosing calculations, or an infusion center billing practice that differs from how UHC calculates units. Quantity-limit denials are appealable when the prescribed quantity is consistent with the FDA label and the patient's documented clinical parameters.

## Your Appeal Rights

Under ACA Section 2719 and ERISA Section 503, you are entitled to a full-and-fair internal appeal and an independent external review if the internal appeal is denied. File your external-review request within four months of the final adverse determination. If interrupting therapy would jeopardize your health, request expedited review for a 72-hour turnaround.

## The Appeal Process

1. Obtain the denial letter and the UHC quantity-limit policy for belimumab — confirm exactly what quantity per period the plan allows. 2. Ask the prescribing physician and infusion pharmacy to confirm that the billed quantity matches the dose calculated per the FDA label for your patient's weight and the dosing frequency specified in the label. 3. File a Level 1 internal appeal with a written explanation of the dosing calculation and supporting documentation. 4. If upheld internally, proceed to external IRO review.

## Documentation to Gather

• FDA prescribing label: Print the current FDA-approved prescribing information for belimumab and highlight the dosing schedule and weight-based calculation method. This is the authoritative source for what quantity is medically appropriate.
• Patient weight and dosing calculation: A note from the prescriber or infusion pharmacist showing the calculation that produces the billed quantity, derived from the label's dosing instructions.
• Infusion records: Facility records showing the actual amount administered per infusion session, confirming no waste or overage.
• Medical-necessity letter: A brief letter from the prescriber confirming the prescribed regimen is consistent with the FDA label and is clinically necessary.
• UHC quantity-limit policy: Obtain this directly from UHC to confirm whether their policy aligns with the label or imposes a more restrictive limit — if the latter, that discrepancy is the core of your appeal argument.

## Criteria-Mapping Structure

Build your appeal around a direct comparison:

| Parameter | FDA Label Value | UHC Policy Value | Patient-Specific Value | |---|---|---|---| | Dosing frequency | (from label) | (from UHC policy) | (from prescriber order) | | Dose per administration | (weight-based per label) | (units authorized per period) | (calculated for patient weight) | | Units per dispensing period | (derived from label) | (plan limit) | (billed quantity) |

If the patient's billed quantity equals the label-calculated quantity, this table makes the case visually clear. If the UHC policy sets a limit below what the label requires for a patient of this weight, the appeal should explicitly request a medical-necessity exception to the quantity limit on that basis.